
New findings on the connection between confidence and aesthetics
In the Triangle's competitive professional landscape, confidence isn't just a feeling — it's a catalyst for success. Raleigh-based Merz Aesthetics, a global medical aesthetics business, recently unveiled the results of their ground breaking study, Pillars of Confidence: Global Insights on Aesthetics and Self-Affirmation revealing how aesthetic treatments can help align our inner selves with our outward appearance to support self-confidence.
Inspired by a purpose to fuel confidence worldwide, Merz Aesthetics undertook this research to spark a new conversation around confidence and the higher-order benefits of aesthetic treatments, grounded in data from 15,000 adults across 15 countries (approximately 1,000 participants per country including the United States).
The impact on self-perception
Merz Aesthetics' research delves into a key question: How do aesthetic treatments impact confidence and self-perception? The findings are illuminating:
74% of U.S. respondents agreed with the statement, "I am confident in who I am."
64% said they use aesthetic treatments to create a look inspired by how they feel inside.
68% reported that treatments impacted how they view themselves.
The research shows what many may have already intuited — aesthetic treatments seem to do more than just enhance appearance; they can help people feel empowered as they embark on their self-confidence journey.
Regional relevance and broader implications
In a region that's frequently ranked among the best places to live and work, businesses could certainly benefit from gaining a better understanding of the role confidence plays in daily life. The Pillars of Confidence study shows that people who feel confident are more likely to embrace new experiences, pursue opportunities and create relationships. Imagine what that could mean for the Triangle's workforce, where attracting top talent, making professional connections and fostering creativity are already top priorities.
These broader benefits are validated by the study's findings. Seventy-five percent of U.S. respondents believe that developing self-confidence is important to one's well-being. When it comes to individual benefits, 69% of U.S. respondents said aesthetic treatments impact their confidence in social situations and 53% agreed that treatments affect their overall outlook on life.
Navigating age perception in the workplace
The research also explores evolving sentiments around aging, making it particularly relevant in our multi-generational workplaces. The Pillars of Confidence study found that, while there are many factors that contribute to people's confidence levels in the workplace, age perception holds a notable amount of influence. In fact, 48 percent of U.S. respondents don't want to be perceived as older than they are and a majority (71%) seek treatments to manage the signs of aging.
A cultural shift toward openness
One of the key insights from the study is an increasing openness around aesthetics. Fifty-five percent of U.S. respondents said they were comfortable discussing treatments, while fewer than 38% feared judgment. This represents a cultural shift toward authenticity that businesses can embrace by creating spaces — both physical and digital — where people feel comfortable and supported in their unique self-confidence journeys.
Transformative effects on personal empowerment
The higher-order impact of aesthetic treatments is striking. After receiving them:
68% of U.S. respondents felt more empowered.
62% said they felt more alive.
54% felt ready to embrace new experiences.
For Triangle employers, these findings suggest that supporting employee confidence — however they choose to cultivate it — may yield benefits in workplace engagement and innovation.
Read more about the Pillars of Confidence Study and get access to the global and regional reports at merzaesthetics.com/confidence.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
an hour ago
- Business Wire
Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND ® in Rare Blood Disorders
AMSTERDAM--(BUSINESS WIRE)--Avanzanite Bioscience B.V. ('Avanzanite'), a fast-growing commercial-stage specialty pharmaceutical company dedicated to bringing rare disease medicines to patients across Europe, announced today an exclusive agreement with Agios Pharmaceuticals Inc. (Nasdaq: AGIO), a Boston-based biotech company focused on the development and commercialization of rare disease medicines. Under the agreement, Avanzanite will commercialize and distribute PYRUKYND® (mitapivat) across the European Economic Area, the UK and Switzerland. 'This partnership marks a major milestone in our mission to transform how rare disease therapies reach patients in Europe' Share 'This partnership marks a major milestone in our mission to transform how rare disease therapies reach patients in Europe,' said Adam Plich, Founder and CEO of Avanzanite. 'We provide biotech partners with a capital-efficient path to sustainable patient access – without the burden of building a costly local infrastructure. We look forward to working with Agios to help bring PYRUKYND® to patients across Europe, further advancing our efforts to set a new benchmark for biotech commercial and distribution partnerships in the region. This is just the beginning.' PYRUKYND®, a first-in-class, oral, pyruvate kinase (PK) activator, is approved by the European Commission and the UK's Medicines and Healthcare products Regulatory Agency for the treatment of adult patients with PK deficiency. PK deficiency is an ultra-rare, inherited condition that causes premature red blood cell breakdown, leading to chronic anemia, serious complications, and reduced quality of life. Until recently, there were no approved treatments. Agios also has a robust mid- and late-stage pipeline, with clinical programs focused on other rare diseases, including thalassemia and sickle cell disease. The partnership also includes potential future indications. Avanzanite is rapidly scaling its operations, having tripled its revenue in Q1 2025 year-over-year, with two rare disease medicines already on the market. Over the next 12 months, the company will expand into 32 European countries, including new territories of Italy, France, the UK, Romania, and Spain. 'Avanzanite goes truly pan-European,' concluded Plich. 'And as we expand across the continent, our promise stays the same – making sure no patient is left behind.' About Avanzanite Avanzanite is redefining launches of rare disease medicines across Europe. Founded in 2022 and based in Amsterdam, the company partners with biotech innovators to unlock the full commercial value of orphan medicines continent-wide. With our deep expertise in market access, we navigate Europe's complex landscape like master chess players – ensuring no patient is left behind. Learn more at
Yahoo
an hour ago
- Yahoo
Compress and Shock Foundation offers free CPR and AED usage training during CPR awareness week
ROANOKE, Va. (WFXR) — As a part of national CPR awareness week, several local healthcare systems partnered with the Roanoke-based Compress and Shock Foundation to host free educational opportunities to equip the public with the skills to save a life. LewisGale Regional Health System partnered with the foundation to host a class at First Baptist Church in Roanoke that taught around 40 participants. 'Sudden cardiac arrest can happen to anyone, anywhere, at any time,' said Jennifer Herriot-Trejo, director of Hispanic outreach for the Compress and Shock Foundation. 'It does not discriminate based on age, race, anything.' Several volunteers, including a few LewisGale nurses, helped to lead small-group training sessions, where participants were able to practice the skills they had been taught. 'I've always had a passion for cardiac patients and it's great to be able to bring this to the community and teach the community how to save lives and make a difference in someone's life one person at a time,' said LewisGale nurse Heather Snyder. The Compress and Shock Foundation offers free CPR and AED usage training, and as part of their 'education day,' on Saturday, they were active across Virginia and around the country alongside regional health partners. Compress & Shock Foundation hosting health fair on CPR and AED awareness LewisGale's parent company, HCA Healthcare, has invested $40,000 into Compress and Shock, which has allowed the foundation to increase the accessibility of AEDs. After Saturday's class in Roanoke, the partnership between Compress and Shock and HCA Healthcare had provided 15 AEDs to a number of communities, with hopes of supplying 10 more by the end of 2025. '[AEDs] need to be in schools, they need to be in churches, they need to be in sports clubs,' said Herriot-Trejo. 'They need to be accessible so that people are prepared for when something happens. It's not a matter of if, it's a matter of when.' Saturday's class was taught bilingually, another component of Compress and Shock's mission to make the knowledge and skills to save a life accessible by all members of the community. According to Herriot-Trejo, non-English speakers often miss out on learning the critical information because of the language barrier. 'We just want to meet people where they are and get things into the languages that they understand,' said Herriot-Trejo. 'So that if they do need to activate their emergency response systems, they're going to feel adequately prepared because they've received that knowledge in their language.' Compress and Shock also partnered with Carilion Clinic to host an education day in Christiansburg. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.


Business Wire
2 hours ago
- Business Wire
Innospera Pharma Appoints Dr. Glenn Crater as Chief Medical Officer to Support Advancement of ING-006 Toward the Clinic
MONTREAL--(BUSINESS WIRE)-- Innospera Pharma Inc. ('Innospera'), a private, near-clinical-stage biotechnology company advancing differentiated small molecule modulators of GPR84 and GPR40 to treat inflammatory and metabolic diseases, today announced the appointment of Dr. Glenn Crater, MD, FCCP as Chief Medical Officer (CMO). Glenn will start immediately as a fractional CMO, with the commitment to joining full time as the Company's lead compound reaches the clinic. A board-certified pulmonologist, Dr. Crater has played pivotal roles in advancing respiratory drug candidates, with particular expertise in Idiopathic Pulmonary Fibrosis (IPF) — the initial target indication for Innospera's lead compound, ING-006 Share Dr. Crater brings to Innospera over 25 years of clinical, regulatory, and leadership experience in pulmonary medicine and drug development. A board-certified pulmonologist, Dr. Crater has played pivotal roles in advancing respiratory drug candidates, with particular expertise in Idiopathic Pulmonary Fibrosis (IPF) — the initial target indication for Innospera's lead compound, ING-006, which is poised to enter clinical development in the near future. 'We are thrilled to welcome Glenn to Innospera at this critical moment in our growth,' said François Ravenelle, PhD, Chief Executive Officer of Innospera. 'Having worked closely with Glenn at Inversago Pharma, I've witnessed first-hand his commitment to scientific rigor, clinical excellence, and patient impact. His deep understanding of IPF and drug development will be invaluable as we initiate clinical studies for ING-006 and build a pipeline of novel GPR84/GPR40 modulators.' Prior to joining Innospera, Dr. Crater served as Chief Medical Officer at multiple biotechnology companies and held senior medical leadership positions across both private and public firms, contributing to successful regulatory submissions and clinical programs in respiratory and fibrotic diseases. 'I'm excited to reunite with François and the team at Innospera,' said Dr. Crater. 'ING-006 represents a promising new approach to modulating inflammation and fibrosis via GPCR lipid signaling. I look forward to advancing this program in the clinic and working to deliver transformative therapies for patients living with IPF and related diseases.' About Innospera Pharma Innospera is a Montreal-based biotechnology company developing first-in-class GPR84 and GPR40 modulators to restore homeostasis in diseases driven by metabolic and inflammatory dysfunction. The company's lead compound, ING-006, is a synthetic lipid designed to address Idiopathic Pulmonary Fibrosis (IPF) by resolving inflammation and reducing fibrogenesis. Innospera is backed by a strong syndicate of investors including Investissement Québec, Seido Capital, and Anges Québec. For more information, visit